Claims:

- 1. A composition exhibiting vWF protease activity comprising at least one single peptide chain having a molecular weight between 190 kD and 100 kD as determined by SDS-PAGE and comprising the amino acid sequence AAGGILHLELLV.
- 2. A composition according to claim 1 wherein said sequence is located at the N-terminus of the peptide chain.
- 3. A composition according to claim 1 wherein said peptide chain has a molecular weight of about 180 kD.
- 4. A composition according to claim 1 wherein said peptide chain has a molecular weight of about 170 kD.
- 5. A composition according to claim 1 wherein said peptide chain has a molecular weight of about 160 kD.
- 6. A composition according to claim 1 wherein said peptide chain has a molecular weight of about 120 kD.
- 7. A composition according to claim 1 wherein said peptide chain has a molecular weight of about 110 kD.
- 8. A composition according to claim 1 wherein said composition cleaves vWF at the peptide bond 842Tyr-843Met.
- 9. A composition according to claim 1 wherein said composition retains activity in the presence of a serine protease inhibitor and a calpain protease inhibitor.

- 10. A composition according to claim 9, wherein said serine protease inhibitor is diisopropyl fluorophosphate.
- 11. A composition according to claim 9, wherein said calpain protease inhibitor is Z-Leu-Leu-Tyr-CHN₂.
- 12. A composition according to claim 1 wherein said peptide chain further comprises the amino acid sequence AVGPDVFQAHQEDTERYV LTNLNIGAELLRDPSLGAQFRVHLVKMVILTEPEGAPNITANLTSSLLSVCGWSQTINPEDD TDPGHADLVLYITRFDLELPDGNRQVRGVTQLGGACSPTWSCLITEDTGFDLGVTI following the sequence AAGGILHLELLV.
- 13. A composition according to claim 1, further comprising Ca²⁺, Sr²⁺ or Ba²⁺ ions.
- 14. A composition according to claim 1 comprising Ca^{2+} ions in a concentration of about 1 to 10^6 per selected polypeptide molecule.
- 15. A composition according to claim 1, wherein said composition is essentially free of vWF or vWF fragments.
- 16. A composition according to claim 1, further comprising clusterin or an analog or derivative thereof.
- 17. An isolated polypeptide having a molecular weight between 180 kD and 100 kD as determined by SDS-PAGE and comprising the amino acid sequence AAGGILHLELLV.

- 18. An isolated polypeptide according to claim 14, wherein said polypeptide further comprises the amino acid sequence AVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILTEPEGAPNITANL TSSLLSVCGWSQTINPEDDTDPGHADLVLYITRFDLELPDGNRQVRGVTQLGGACSPTWS CLITEDTGFDLGVTI directly following the amino acid sequence AAGGILHLELLV.
- 19. An isolated polypeptide according to claim 18 having a molecular weight of about 170 kD.
- 20. An isolated polypeptide according to claim 18 having a molecular weight of about 160 kD.
- 21. An isolated polypeptide according to claim 18 having a molecular weight of about 120 kD.
- 22. An isolated polypeptide according to claim 18 having a molecular weight of about 110 kD.
- 23. A vWF cleaving complex comprising a polypeptide according to claim 18 and a divalent metal ion selected from the group consisting of Ca⁺⁺, Sr⁺⁺ and Ba⁺⁺.
- 24. A vWF cleaving complex according to claim 23 wherein the divalent cation is Ca⁺⁺.
- 25. A vWF cleaving complex comprising a complex according to claim 23, further containing vWF.
- 26. A composition comprising a polypeptide which comprises the sequence AAGGILHLELLV.

- 27. Use of a composition according to claim 14 for the development of anti-peptide antibodies or derivatives thereof.
- 28. A method of purifying von Willebrand factor comprising contacting a solution containing von Willebrand factor with a polypeptide substrate comprising the amino acid sequence AAGGILHLELLV under conditions sufficient to bind von Willebrand factor to the substrate.
- 29. A composition according to claim 18, wherein the amino acid sequence is encoded by the polynucleotide according to Fig. 2.
- 30. An isolated polypeptide having vWF protease activity wherein said polypeptide comprises the amino acid sequence AAGGILHLELLVAVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILTE PEGAPNITANLTSSLLSVCGWSQTINPEDDTDPGHADLVLYITRFDLELPDGNRQVRGVTQ LGGACSPTWSCLITEDTGFDLGVTI.
- 31. An isolated polypeptide according to claim 30 wherein said polypeptide is encoded by a polynucleotide sequence according to Fig. 2.
- 32. A host cell and progeny thereof containing a polynucleotide according to Fig. 2.
- 33. A method for the production of a polypeptide exhibiting vWF protease activity comprising
- growing, in a nutrient medium, a host cell comprising an expression vector comprising, in the direction of transcription, a transcriptional regulatory region and a translational initiation region functional in a host cell,
- a cDNA sequence encoding for a polypeptide according to claim 18, wherein said cDNA comprises the sequence according to Fig. 2 and
- transcriptional and translational termination regions functional in said host cell,

wherein the expression of said DNA is regulated by said initiation and termination regions, and

isolating said polypeptide.

- 34. Use of a polypeptide according to claim 18 for the production of a preparation for the prophylaxis or therapy of thrombosis and thromboembolic diseases.
- 35. Use according to claim 35, wherein the disease can be selected from the group consisting of thrombotic thrombocytic purpura (TTP), Henoch-Schönlein purpura, preeclampsia, neonatal thrombocytopenia or hemolyticuremic syndrome.